Author

Gilles Catimel

Observed names: G Catimel, G. Catimel

Observed institutions: European Organisation for Research and Treatment of Cancer, TUM Klinikum, Medizinische Hochschule Hannover, Bristol-Myers Squibb (United States), Antwerp University Hospital, Centre Léon Bérard, Hôpital Lyon Sud, European Organisation for Research and Treatment of Cancer, Japan Breast Cancer Research Group, Cross Cancer Institute, Technical University of Munich

OpenAlex ID: A5032321264

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

1996 · J M Nabholtz, K Gelmon, et al. · Journal of Clinical Oncology · 374

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

1994 · G. Catimel, J. Verweij, et al. · Annals of Oncology · 256

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1995 · D.J.Th. Wagener, H.E.R. Verdonk, et al. · Annals of Oncology · 176

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1995 · G.G. Chabot, D. Abigerges, et al. · Annals of Oncology · 172

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

1994 · Q.G.C. M. van Hoesel, J. Verweij, et al. · Annals of Oncology · 143

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck

1994 · G. Catimel, J.B. Vermorken, et al. · Annals of Oncology · 132

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials

2000 · T. Bachelot, I. Ray-Coquard, et al. · Annals of Oncology · 120

PDF

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1995 · G. Catimel, G.G. Chabot, et al. · Annals of Oncology · 111

PDF

Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck

1999 · P. Schöffski, G. Catimel, et al. · Annals of Oncology · 104

PDF

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer

1999 · A.S.T. Planting, G. Catimel, et al. · Annals of Oncology · 98

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.

1997 · G Giaccone, S C Linn, et al. · PubMed · 84

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

1997 · Y Merrouche, J M Extra, et al. · Journal of Clinical Oncology · 52

Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens

1998 · Isabelle Ray-Coquard, Pierre Biron, et al. · Cancer · 42

PDF

345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)

1995 · T. Peretz, A. Sulkes, et al. · European Journal of Cancer · 39

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

1996 · B. Chevallier, P. Cappelaere, et al. · Supportive Care in Cancer · 34

Phase II clinical trials with rhizoxin in breast cancer and melanoma

1996 · A-R Hanauske, G Catimel, et al. · British Journal of Cancer · 34

PDF

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

1996 · J.P. Armand, Y.M. Extra, et al. · Annals of Oncology · 32

Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients

1996 · Dany Ablgerges, Jean-Pierre Armand, et al. · Anti-Cancer Drugs · 32

Phase II studies of docetaxel in the treatment of various solid tumours

1995 · J. Verweij, G. Catimel, et al. · European Journal of Cancer · 31

Breast cancer: Chemotherapy in the treatment of advanced disease

1993 · M. Clavel, G. Catimel · European Journal of Cancer · 30

Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a

1994 · T. Zenone, G. Catimel, et al. · European Journal of Cancer · 28

Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.

1996 · G Catimel, M Spielmann, et al. · PubMed · 26

Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

1998 · Brigitte Tranchand, Gilles Catimel, et al. · Cancer Chemotherapy and Pharmacology · 25

Head and Neck Cancer

1996 · Gilles Catimel · Drugs · 23

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

1994 · Gilles Catimel, Régis Coquard, et al. · Cancer Chemotherapy and Pharmacology · 21

Works count: 53

Citation count: 2,406

H-index: 23

I10-index: 34